Corporate Responsibility Report

Overview

The report highlights Guardant Health's 2024 product progress, including FDA approval and launch of the Shield blood test and Medicare coverage for colorectal cancer monitoring. It reports 2,021 employees at December 31, 2024, with 54% female, and describes expanded learning, inclusion and employee engagement efforts. The company also details board ESG oversight, responsible supply-chain initiatives, and an initial 2023 Scope 1 and Scope 2 emissions assessment. Environmental disclosures note approximately 192,000 pounds of hazardous and medical waste generated in 2024.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services